AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9164591
Drug: d-amphetamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (10 or 20 mg)
Trial: 3618993
Drug: Pre-operative medication
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative medication
Trial: 20210697
Drug: Anti-muscarinic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-muscarinic treatment alone (4 mgs of tolterodine orally for 12 weeks)
Trial: 17620783
Drug: Oral fluid
RxNorm normalized name: cascara sagrada ORAL FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluid therapy
Trial: 15815811
Drug: Preservative-containing saline
RxNorm normalized name: CONTACT LENS SALINE,PRESERVED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-containing saline solution during BTX-A injections in the upper face (n = 60)
Trial: 15815811
Drug: Preservative-containing saline
RxNorm normalized name: CONTACT LENS SALINE,PRESERVED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-containing saline solution during BTX-A injections in the neck (n = 15)
Trial: 15815811
Drug: Preservative-containing saline
RxNorm normalized name: CONTACT LENS SALINE,PRESERVED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-containing saline solution during BTX-A injections in the axillary region (n = 18)
Trial: 15815811
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preservative-containing saline solution) in the upper face (n = 60)
Trial: 15815811
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preservative-containing saline solution) in the neck (n = 15)
Trial: 15815811
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preservative-containing saline solution) in the axillary region (n = 18)
Trial: 10425979
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of trazodone
Trial: 2192369
Drug: Tulobuterol 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol 2.0 mg
Trial: 7042370
Drug: Penbutolol 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol 40 mg once a day
Trial: 19918965
Drug: Intravaginal progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravaginal progesterone gel, 90 mg daily
Trial: 9655769
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg fructose (placebo)
Trial: 7658819
Drug: Cefuroxime (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (4.5 g/day intravenously) from admission
Trial: 7658819
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic treatment until clinical or microbiologically verified infection
Trial: 2787297
Drug: Midazolam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.2 mg/kg i.v.)
Trial: 2787297
Drug: Diazepam (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.4 mg/kg i.v.)
Trial: 820228
Drug: Low-dose intramuscular
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intramuscular insulin therapy
Trial: 820228
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin therapy (intravenous and subcutaneous)
Trial: 28007428
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% azithromycin applied twice daily for 3 consecutive days
Trial: 28007428
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied twice daily for 3 consecutive days
Trial: 28007428
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% azithromycin
Trial: 21701268
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solution (HSS) with furosemide (250 mg) and moderate Na restriction (120 mmol)
Trial: 21701268
Drug: Furosemide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (250 mg) without HSS and low Na diet (80 mmol)
Trial: 19798725
Drug: rAAV1.tMCK.hSGCA gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV1.tMCK.hSGCA gene therapy
Trial: 26341174
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g tranexamic acid
Trial: 15526307
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER 75-150 mg/day
Trial: 15526307
Drug: Citalopram 10-20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 10-20 mg/day
Trial: 9391919
Drug: Alcohol (0.62
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.62 g/kg for men, 0.54 g/kg for women)
Trial: 7349932
Drug: Individual advice
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual advice twice a year and health education campaign in intervention factories
Trial: 31821220
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (HDG): three 90-minute yoga classes and four 30-minute homework sessions per week for 12 weeks.
Trial: 31821220
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (LDG): two 90-minute yoga classes and three 30-minute homework sessions per week for 12 weeks.
Trial: 28946736
Drug: Lamivudine (LAM)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine (LAM) 100 mg/day
Trial: 25897158
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg intravenously once every 2 weeks for up to 96 weeks
Trial: 25897158
Drug: Nivolumab 1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1, 3, or 10 mg/kg intravenously once every 2 weeks for up to 96 weeks
Trial: 21873705
Drug: Colchicine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1.0 to 2.0 mg on the first day followed by 0.5 to 1.0 mg/d for 6 months)
Trial: 19688320
Drug: Yinzhihuang Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yinzhihuang Oral Liquid (YOL), 5 mL each time, twice daily
Trial: 15474732
Drug: Transgenic corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transgenic corn expressing 1 mg of LT-B, fed in three doses of 2.1 g each.
Trial: 11528274
Drug: Volatile oil
RxNorm normalized name: Volatile oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volatile oil administered by gargling for 14 consecutive nights
Trial: 27338807
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 14 consecutive nights
Trial: 8805169
Drug: Gentamicin sulfate
RxNorm normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin sulfate (5 mg/kg daily) for > 10 days
Trial: 8805169
Drug: Gentamicin sulfate
RxNorm normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin sulfate (5 mg/kg daily) for <= 7 days
Trial: 6236095
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ipratropium bromide and Fenoterol (Ip/Fen)
Trial: 28433267
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg vitamin D3
Trial: 28433267
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg calcifediol
Trial: 28433267
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg calcifediol
Trial: 28433267
Drug: Calcifediol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcifediol (10 and 15 μg)
Trial: 25078385
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine
Trial: 27507582
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (TAP, intravenous lignocaine, placebo)
Trial: 25618125
Drug: High-frequency ultrasound
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency ultrasound (HFU) therapy
Trial: 25618125
Drug: MIST ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIST ultrasound therapy
Trial: 25618125
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy (HFU and MIST combined)
Trial: 25618125
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (HFU, MIST, and Standard treatment)
Trial: 21262931
Drug: 20 per
RxNorm normalized name: evolocumab 420 per 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 per cent carbamide peroxide (CP) at-home bleaching agent, bonded 24 hours after bleaching (n = 40)
Trial: 21262931
Drug: 20 per
RxNorm normalized name: evolocumab 420 per 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 per cent carbamide peroxide (CP) at-home bleaching agent, bonded 14 days after bleaching (n = 40)
Trial: 17686443
Drug: Enzastaurin (novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin (novel targeted therapy, monotherapy)
Trial: 17686443
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and pemetrexed (new drugs)
Trial: 17686443
Drug: Pharmacogenomics (tailored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenomics (tailored therapy)
Trial: 16335170
Drug: Early loading
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loading group (20 implants); mean change in ISQ: -0.08 +/- 0.77; mean bone loss: 0.69 +/- 0.15 mm.
Trial: 16335170
Drug: Unloaded group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unloaded group (21 implants); mean change in ISQ: 1.33 +/- 1.65; mean bone loss: 0.53 +/- 0.18 mm.
Trial: 2160358
Drug: Long-acting propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting propranolol 60 mg once a day for 12 weeks
Trial: 2160358
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg once a day for 12 weeks
Trial: 6113920
Drug: Tiotidine 25
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotidine 25 mg
Trial: 6113920
Drug: Tiotidine 50
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotidine 50 mg
Trial: 6113920
Drug: Tiotidine 100
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotidine 100 mg
Trial: 6113920
Drug: Tiotidine 150
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotidine 150 mg
Trial: 24704942
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy and endobronchial photodynamic therapy (PDT) with photosensitizer agent chlorine E6 and 662nm laser light before each of the three courses of chemotherapy.
Trial: 24704942
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (No-PDT arm).
Trial: 24704942
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy and endobronchial PDT (PDT arm).
Trial: 22791944
Drug: Epidural combined
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural combined general anesthesia (G + E)
Trial: 15385354
Drug: Neostigmine 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the first tactile TOF response (Group I)
Trial: 15385354
Drug: Neostigmine 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the second tactile TOF response (Group II)
Trial: 15385354
Drug: Neostigmine 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the third tactile TOF response (Group III)
Trial: 15385354
Drug: Neostigmine 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the fourth tactile TOF response (Group IV)
Trial: 15385354
Drug: Neostigmine 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the first tactile TOF response (Group I) during sevoflurane anesthesia
Trial: 15385354
Drug: Neostigmine 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the second tactile TOF response (Group II) during sevoflurane anesthesia
Trial: 15385354
Drug: Neostigmine 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the third tactile TOF response (Group III) during sevoflurane anesthesia
Trial: 15385354
Drug: Neostigmine 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the fourth tactile TOF response (Group IV) during sevoflurane anesthesia
Trial: 11477585
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using meta-tetra(hydroxyphenyl)chlorin (m-THPC) at a dose of 0.10 mg/kg bodyweight, irradiated 48 hours after drug application at a light dose of 5 J/cm².
Trial: 11477585
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using meta-tetra(hydroxyphenyl)chlorin (m-THPC) at a dose of 0.15 mg/kg bodyweight, illuminated 96 hours after photosensitization at a light dose of 10 J/cm².
Trial: 11477585
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using m-THPC.
Trial: 9748876
Drug: Sequential maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential maintenance therapy (interferon alpha-2b for 3 months followed by dexamethasone)
Trial: 9748876
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with melphalan (200 mg/m2)
Trial: 6840159
Drug: Nifedipine 60
RxNorm normalized name: nifedipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 60 mg
Trial: 7317899
Drug: Nifedipine 90
RxNorm normalized name: nifedipine 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 90 mg
Trial: 31119583
Drug: Diet 2
RxNorm normalized name: gluc-msm-vit C-FA-mang-diet 29 125 mg-37.5 mg-25 mg-500 mcg-1.25 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 2 (10 g kg−1 CDXOS)
Trial: 31119583
Drug: Diet 3
RxNorm normalized name: Phendiet 35 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 3 (108 CFU g−1 L. plantarum CR1T5)
Trial: 31119583
Drug: Diet 4
RxNorm normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 4 (10 g kg−1 CDXOS + 108 CFU g−1 L. plantarum CR1T5)
Trial: 8181024
Drug: Loop diuretic
RxNorm normalized name: Loop diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretic
Trial: 20151804
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (SDD; 20 mg two times a day)
Trial: 17531899
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of gestational diabetes mellitus (GDM)
Trial: 16109560
Drug: Epi-CH (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epi-CH (10 mg Epi-CH injected around the primary tumor or biopsy excision 72 h before operation)
Trial: 16109560
Drug: Control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (10 mg epirubicin solution injected in the same region)
Trial: 2572037
Drug: Broxaterol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broxaterol (400 micrograms by metered dose inhaler)
Trial: 2572037
Drug: Broxaterol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broxaterol (0.5 mg by oral route)
Trial: 2572037
Drug: Broxaterol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broxaterol (0.25 mg as nebulizer solution)
Trial: 2572037
Drug: Broxaterol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broxaterol (oral and aerosol administration)
Trial: 27595680
Drug: Apixaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (5 mg BID, with a possible reduction to 2.5 mg BID based on certain criteria; single starting dose of 10 mg or 5 mg if down-titrated)
Trial: 27595680
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus warfarin
Trial: 18608712
Drug: Isotretinoin (Iso)
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin (Iso) therapy for cystic acne for 45 days
Trial: 18608712
Drug: Isotretinoin (Iso)
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin (Iso) therapy for cystic acne
Trial: 12381942
Drug: High-dose calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose calcium acetate (1,521 mg calcium/day)
Trial: 12381942
Drug: Low-dose calcium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose calcium acetate (507 mg calcium/day)
Trial: 7781936
Drug: Antibiotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic group (500 mg amoxicillin q.i.d. and 500 mg tinidazole t.i.d. for 1 week)
Trial: 7781936
Drug: Maintenance group
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance group (40 mg famotidine for 6 weeks followed by 20 mg famotidine at bedtime for 6 months)
Trial: 29700480
Drug: Antibiotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic group
Trial: 7781936
Drug: Antibiotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic group (H. pylori negative)
Trial: 2195108
Drug: Insulin 3
RxNorm normalized name: Pen Needle Insulin 33 gauge 4mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 3 U/h and glucagon 200 micrograms/h in 5% dextrose with 1% human albumin solution (HAS)
Trial: 1959860
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and glucagon therapy
Trial: 44117
Drug: tween‐ether‐split‐vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tween‐ether‐split‐vaccine
Trial: 44117
Drug: subunit‐vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subunit‐vaccine
Trial: 29100778
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with tuberculosis regimen
Trial: 25892434
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment with loperamide and stool-bulking agents (2 months)
Trial: 25892434
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (biofeedback + medical treatment)
Trial: 19920269
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention (bimonthly tailored, nurse-administered telephone intervention targeting hypertension-related behaviors)
Trial: 19920269
Drug: Home BP
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home BP monitoring (3 times weekly)
Trial: 11923755
Drug: Injection therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection therapy with epinephrine‐polidocanol (1%)
Trial: 11923755
Drug: Injection combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection combined with hemoclip
Trial: 9874432
Drug: Ranitidine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (3 x 50 mg intravenously)
Trial: 9874432
Drug: Pirenzepine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (3 x 10 mg intravenously)
Trial: 7711365
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for chronic low-back pain
Trial: 2560684
Drug: Glucagon (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (1 mg s.c.)
Trial: 2560684
Drug: Insulin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.2 U/kg i.v., ITT)